Literature DB >> 24233892

Predictors of severe hypotension in neurocritical care patients sedated with propofol.

G Morgan Jones1, Bruce A Doepker, Michael J Erdman, Lauren A Kimmons, Lucas Elijovich.   

Abstract

INTRODUCTION: Propofol is used extensively in neurocritical care (NCC) due to its pharmacologic properties allowing for facilitation of serial neurologic examinations. Despite widespread use, few studies have identified risk factors for hypotension in these patients. We aimed to determine predictors of hypotension in NCC patients sedated with propofol.
METHODS: This retrospective, multicenter study evaluated 237 patients at two academic medical centers, both with dedicated NCC teams led by board-certified neurointensivists. Univariate analyses were performed to determine risk factors associated with severe hypotension during sedation with propofol. Multivariable analysis was performed to determine variables independently associated with hypotension, defined as a mean arterial pressure (MAP) less than 60 mmHg.
RESULTS: There was an average maximum reduction in MAP of 28.8 % after propofol initiation in the entire cohort. Severe hypotension developed in 62 (26.2 %) patients to a median nadir MAP of 56 mmHg. Those who developed severe hypotension had a longer median duration of mechanical ventilation (5.0 vs. 3.6 days; p = 0.01) and an increased in-hospital mortality (38.7 vs. 24.0 %; p = 0.03). Multivariable logistic regression analysis identified increasing number of changes to the propofol infusion rate, baseline MAP 60-70 mmHg, and need for renal replacement therapy (RRT) as factors independently associated with hypotension.
CONCLUSIONS: Multiple factors predicted hypotension in NCC patients receiving propofol. Clinicians should use propofol cautiously in patients with a lower baseline MAP or receiving RRT. Development of protocols related to the frequency of dose titrations is also recommended to prevent this avoidable complication.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24233892     DOI: 10.1007/s12028-013-9902-6

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  32 in total

1.  Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials.

Authors:  Stephan M Jakob; Esko Ruokonen; R Michael Grounds; Toni Sarapohja; Chris Garratt; Stuart J Pocock; J Raymond Bratty; Jukka Takala
Journal:  JAMA       Date:  2012-03-21       Impact factor: 56.272

2.  Midazolam versus propofol for long-term sedation in the ICU: a randomized prospective comparison.

Authors:  A A Weinbroum; P Halpern; V Rudick; P Sorkine; M Freedman; E Geller
Journal:  Intensive Care Med       Date:  1997-12       Impact factor: 17.440

3.  Cardiovascular responses during sedation after coronary revascularization. Incidence of myocardial ischemia and hemodynamic episodes with propofol versus midazolam. Institutions of the McSPI Research Group.

Authors:  J A Wahr; J J Plunkett; J G Ramsay; J Reeves; U Jain; C Ley; R Wilson; D T Mangano
Journal:  Anesthesiology       Date:  1996-06       Impact factor: 7.892

4.  Transient systolic hypotension. A serious problem in the management of head injury.

Authors:  R J Winchell; R K Simons; D B Hoyt
Journal:  Arch Surg       Date:  1996-05

5.  Use of intravenous infusion sedation among mechanically ventilated patients in the United States.

Authors:  Hannah Wunsch; Jeremy M Kahn; Andrew A Kramer; Gordon D Rubenfeld
Journal:  Crit Care Med       Date:  2009-12       Impact factor: 7.598

6.  Effects of propofol on the leukocyte nitric oxide pathway: in vitro and ex vivo studies in surgical patients.

Authors:  J A González-Correa; E Cruz-Andreotti; M M Arrebola; J A López-Villodres; M Jódar; J P De La Cruz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-07       Impact factor: 3.000

7.  Comparative study of propofol versus midazolam in the sedation of critically ill patients: results of a prospective, randomized, multicenter trial.

Authors:  C Chamorro; F J de Latorre; A Montero; J A Sánchez-Izquierdo; A Jareño; J A Moreno; E Gonzalez; M Barrios; J L Carpintero; F Martín-Santos; B Otero; R Ginestal
Journal:  Crit Care Med       Date:  1996-06       Impact factor: 7.598

8.  Both clonidine and metoprolol modify anesthetic depth indicators and reduce intraoperative propofol requirement.

Authors:  Indranil Ghosh; Parmod K Bithal; Hari H Dash; Arvind Chaturvedi; Hemanshu Prabhakar
Journal:  J Anesth       Date:  2008-05-25       Impact factor: 2.078

Review 9.  Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit.

Authors:  Juliana Barr; Gilles L Fraser; Kathleen Puntillo; E Wesley Ely; Céline Gélinas; Joseph F Dasta; Judy E Davidson; John W Devlin; John P Kress; Aaron M Joffe; Douglas B Coursin; Daniel L Herr; Avery Tung; Bryce R H Robinson; Dorrie K Fontaine; Michael A Ramsay; Richard R Riker; Curtis N Sessler; Brenda Pun; Yoanna Skrobik; Roman Jaeschke
Journal:  Crit Care Med       Date:  2013-01       Impact factor: 7.598

10.  Comparison of propofol and midazolam for sedation in intensive care unit patients.

Authors:  K P Ronan; T J Gallagher; B George; B Hamby
Journal:  Crit Care Med       Date:  1995-02       Impact factor: 7.598

View more
  3 in total

Review 1.  Endoscopist-directed propofol: pros and cons.

Authors:  Eun Hye Kim; Sang Kil Lee
Journal:  Clin Endosc       Date:  2014-03-31

2.  Comparison of Ketofol (Combination of Ketamine and Propofol) and Propofol Anesthesia in Aneurysmal Clipping Surgery: A Prospective Randomized Control Trial.

Authors:  Ajit Bhardwaj; Nidhi Panda; Rajeev Chauhan; Summit Dev Bloria; Neerja Bharti; Hemant Bhagat; Vishwanath Bhaire; Ankur Luthra; Rajesh Chhabra; Shalvi Mahajan
Journal:  Asian J Neurosurg       Date:  2020-08-28

3.  Adverse events of conscious sedation using midazolam for gastrointestinal endoscopy.

Authors:  Jeeyoung Jun; Jong In Han; Ae Lee Choi; Youn Jin Kim; Jong Wha Lee; Dong Yeon Kim; Minjin Lee
Journal:  Anesth Pain Med (Seoul)       Date:  2019-10-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.